THC-Dominant Formulation (Low/No CBD)
Little CBD present; THC drives a strong psychoactive response.
- 0:1: CBD:THC ratio (THC-dominant formulation)
- ~85%: Psychoactive intensity (peak subjective high)
- ~40%: Anxiety/paranoia risk (in susceptible individuals)
- 10–30 min: Onset window (typical inhaled route)
What THC does at high proportion
Binds CB1 receptors strongly; drives the classic euphoric high.
Higher THC share tracks with stronger subjective intensity.
Anxiety and paranoia susceptibility
Some users report heightened anxiety at high unopposed THC doses.
Who tends to choose this profile
Recreational or strong-effect seekers prioritizing intensity over control.
Balanced CBD:THC Product
Equal parts CBD and THC; CBD proposed to blunt THC's edge.
- 1:1: CBD:THC ratio (balanced formulation)
- ~45%: Psychoactive intensity (moderated by CBD)
- ~20%: Anxiety/paranoia risk (reduced vs THC-only)
- ~50%: Relief likelihood (partial symptom coverage)
Proposed CBD-THC interaction
CBD is proposed to modulate CB1 signaling triggered by THC.
A 1:1 ratio is a common starting point in balanced products.
Effect on anxiety-provoking potential
Anxiety risk trends lower than THC-dominant formulations at same dose.
Typical use case
Users wanting some psychoactive effect with softer edges.
High-CBD, Low-THC Product
CBD dominates; minimal psychoactivity, symptom-focused profile.
- 8:1: CBD:THC ratio (high-CBD formulation)
- ~12%: Psychoactive intensity (minimal subjective high)
- ~6%: Anxiety/paranoia risk (markedly reduced)
- ~78%: Relief w/o impairment (symptom-focused likelihood)
Why intensity drops sharply
High CBD share dampens THC's psychoactive contribution substantially.
Minimal "high" while cannabinoid effects are still present.
CBD's own proposed effects
CBD's independent effects become more noticeable at this ratio.
Typical use case
Symptom relief sought without significant impairment.
CBD-Only Product (No THC)
No THC present; purely CBD's proposed effects.
- 20:1+: CBD:THC ratio (effectively CBD-only)
- ~0%: Psychoactive intensity (no psychoactivity)
- ~2%: Anxiety/paranoia risk (near-baseline)
- ~70%: Relief likelihood (CBD-attributed, debated extent)
Absence of psychoactivity
No THC means no intoxicating "high" from this product.
Purely CBD-driven profile with no THC contribution.
Proposed CBD-only effects
Any reported effects are attributed to CBD alone here.
Typical use case
Users avoiding impairment entirely, e.g. daytime use.
Ratio Selection Tailors the Effect
Ratio choice tunes relief-focused vs stronger psychoactive outcomes.
- 0:1–20:1: Ratio range explored (full formulation span)
- Relief ↔ high: Use-case span (two ends of spectrum)
- 5–100 mg: Dose range (adjustable total dose)
- User-tailored: Design principle (ratio matched to goal)
High-CBD end of the spectrum
Favors symptom relief with minimal impairment.
CBD-dominant ratios trade intensity for control.
THC-dominant end of the spectrum
Favors stronger psychoactive, recreational-style effect.
Balanced ratios as middle ground
Intermediate option between relief and intensity.